1. Home
  2. PTCT vs FHI Comparison

PTCT vs FHI Comparison

Compare PTCT & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTCT
  • FHI
  • Stock Information
  • Founded
  • PTCT 1998
  • FHI 1955
  • Country
  • PTCT United States
  • FHI United States
  • Employees
  • PTCT N/A
  • FHI N/A
  • Industry
  • PTCT Biotechnology: Pharmaceutical Preparations
  • FHI Investment Managers
  • Sector
  • PTCT Health Care
  • FHI Finance
  • Exchange
  • PTCT Nasdaq
  • FHI Nasdaq
  • Market Cap
  • PTCT 3.9B
  • FHI 3.4B
  • IPO Year
  • PTCT 2013
  • FHI N/A
  • Fundamental
  • Price
  • PTCT $50.73
  • FHI $49.54
  • Analyst Decision
  • PTCT Buy
  • FHI Hold
  • Analyst Count
  • PTCT 14
  • FHI 7
  • Target Price
  • PTCT $67.64
  • FHI $42.57
  • AVG Volume (30 Days)
  • PTCT 1.0M
  • FHI 514.2K
  • Earning Date
  • PTCT 08-07-2025
  • FHI 07-31-2025
  • Dividend Yield
  • PTCT N/A
  • FHI 2.76%
  • EPS Growth
  • PTCT N/A
  • FHI 2.09
  • EPS
  • PTCT 7.51
  • FHI 3.58
  • Revenue
  • PTCT $1,772,758,000.00
  • FHI $1,659,262,000.00
  • Revenue This Year
  • PTCT $120.38
  • FHI $5.75
  • Revenue Next Year
  • PTCT N/A
  • FHI $3.82
  • P/E Ratio
  • PTCT $6.60
  • FHI $13.78
  • Revenue Growth
  • PTCT 91.12
  • FHI 2.19
  • 52 Week Low
  • PTCT $29.02
  • FHI $31.94
  • 52 Week High
  • PTCT $58.38
  • FHI $49.70
  • Technical
  • Relative Strength Index (RSI)
  • PTCT 54.87
  • FHI 74.28
  • Support Level
  • PTCT $44.15
  • FHI $48.46
  • Resistance Level
  • PTCT $47.61
  • FHI $49.43
  • Average True Range (ATR)
  • PTCT 1.74
  • FHI 0.73
  • MACD
  • PTCT -0.12
  • FHI 0.12
  • Stochastic Oscillator
  • PTCT 81.20
  • FHI 88.64

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

About FHI Federated Hermes Inc.

Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).

Share on Social Networks: